Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 4;11:1135–1146. doi: 10.2147/DDDT.S131487

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Woo et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

The pharmacodynamic and pharmacokinetic differences according to each genotype of SLCO1B1 c.-910G>A, SLCO1B3 c.334G>T, and ABCC2 c.1249G>A.

Notes: The box-and-whisker plots of the area under the plasma concentration curve from hour 0 to infinity (AUC_∞), clearance adjusted with body weight (CL_adj) and maximum concentration (C_max) of atorvastatin, and percentage changes in total cholesterol (%ΔTC) and LDL-C (%ΔLDL-C) from baseline to 48 hours after atorvastatin administration according to genetic polymorphisms, are presented. There were differences in C_max according to SLCO1B1 c.-910G >A and SLCO1B3 c.334G>T genotypes, and %ΔTC and %ΔLDL-C between G/G and G/A genotypes of ABCC2 c.1249G>A.